Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
Mult Scler. 2009 Oct;15(10):1175-82. doi: 10.1177/1352458509107007.

Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.

Author information

  • 1Department of Neurology, University of California, San Francisco, CA 94143-0114, USA. douglas.goodin@ucsf.edu

Abstract

Multiple sclerosis is a chronic, demyelinating disorder of the central nervous system. It is characterised by progressive neurological disability, which is likely to occur as a result of permanent axonal damage. Such damage may be reflected by brain atrophy, which can be identified early in the course of the disease. Patients who present with an initial episode of inflammatory demyelination, commonly referred to as a clinically isolated syndrome, are at high risk of developing clinically definite multiple sclerosis, especially if their magnetic resonance imaging studies suggest the presence of multi-focal disease. Treatment with disease-modifying therapies at the initial episode of demyelination may postpone this development. In this review we present an overview of evidence supporting early treatment initiation. We focus on three large placebo-controlled trials of interferon beta therapy: Controlled High-Risk Avonex Multiple Sclerosis Prevention Study, Early Treatment of Multiple Sclerosis and Betaferon in Newly Emerging Multiple Sclerosis for Initial Treatment. Results from these early treatment studies are presented, and the impact of using interferon beta treatment in the early stages of disease is discussed with the aim of considering optimal therapeutic strategies to improve long-term patient outcome.

Comment in

PMID:
19737851
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Write to the Help Desk